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The California poppy (Eschscholzia californica Cham.) contains a variety of natural compounds including several alkaloids found
exclusively in this plant. Because of the sedative, anxiolytic, and analgesic effects, this herb is currently sold in pharmacies in many
countries. However, our understanding of these biological effects at the molecular level is still lacking. Alkaloids detected in E.
californica could be hypothesized to act at GABAA receptors, which are widely expressed in the brain mainly at the inhibitory
interneurons. Electrophysiological studies on a recombinant 𝛼
1
𝛽
2
𝛾
2
GABAA receptor showed no effect of N-methyllaurotetanine
at concentrations lower than 30𝜇M. However, (𝑆)-reticuline behaved as positive allosteric modulator at the 𝛼
3
, 𝛼
5
, and 𝛼
6
isoforms
of GABAA receptors. The depressant properties of aerial parts of E. californica are assigned to chloride-current modulation by (𝑆)-
reticuline at the 𝛼
3
𝛽
2
𝛾
2
and 𝛼
5
𝛽
2
𝛾
2
GABAA receptors. Interestingly, 𝛼1, 𝛼3, and 𝛼5 were not significantly affected by (𝑅)-reticuline,
1,2-tetrahydroreticuline, codeine, and morphine—suspected (𝑆)-reticuline metabolites in the rodent brain.
1. Introduction
The California poppy is known in folk medicine for its
sedative, anxiolytic, and antinociceptive effects [1–4]. These
effects have been traditionally assigned to protopine and
allocryptopine (see Figure 1). Both alkaloids act as weak
stimulators of the binding of GABAA receptor agonists in the
rat brain [5, 6], as anti-inflammatory agents [7] and as acetyl-
cholinesterase inhibitors [7, 8]. Another aporphine alka-
loid isolated from this plant, namely, N-methyllaurotetanine
(NMT), was reported to act as antagonist at the serotonin
5HT1AR receptor (EC50 = 155 nM,𝐾𝑖 = 85 nM) [9]. Protopine
and allocryptopinewere also found to block human serotonin
and noradrenaline transporters (hSERT and NERT) and
possess antidepressant-like effects on animal models [10].
However, it is not clear whether typical pharmacy prepara-
tions (i.e., 300mg of dry plant material per capsule) contain
sufficient quantities of these alkaloids required to induce
desired biological effects. Even though the presence of NMT
in this plant has been clearly established, its content in the
aerial parts of this perennial herb is currently unknown.
Furthermore, it is not known whether or not this molecule
interacts with the GABAA receptor.
In the present work, we have studied total alkaloid extrac-
tion from aerial parts of E. californica by two methods. First,
the standard chloroform/SDS method [11] relying on the ion
pairing of alkaloids with an anionic detergent (Method A)
was used. Second, the dry plant was macerated for extended
period of time in methanol solutions, solution pH was
adjusted, and alkaloids were extracted into diethylether [12]
(Method B). Alkaloids contained in different fractions were
analysed using the diode-array spectrophotometer coupled to
HPLC and with the electrospray-tandem MS/MS spectrom-
etry (ESI-MS/MS). The main goal of the present study was
to identify the active principle in E. californica responsible
for reported sedative and anxiolytic effects [1–4]. Finally, we
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Figure 1: Alkaloids identified in the aerial parts of Eschscholzia californica.
would like to conclude with whether this medicinal herb
has a potential of replacing some commonly used synthetic
sleeping drugs and antidepressants.
2. Material and Methods
2.1. Chemicals. Protopine hydrochloride (≥98%) and 𝛼-
allocryptopine (≥98%) were obtained from Sigma-Aldrich
(Switzerland). (S)-(+)-Reticuline hydrochloride (95%, >90%
ee), (R)-(−)-reticuline (95%), and 1,2-tetrahydroreticuline
iodide (95%) used in electrophysiological experiments at
the GABAA receptors were obtained from Toronto Research
Chemicals (Canada). Morphine sulphate salt pentahydrate
(99.8%) and codeine certified reference material (1mg/mL in
methanol) were obtained from Sigma. Caryachine (98%) and
O-methylcaryachine (98%) samples were kindly provided by
Stefan Gafner (Tom’s of Maine, USA).
2.2. Alkaloid Extraction Analysis. The alkaloid extraction
procedure (Method A) employed in the present study was
slightly modified as compared to the original protocol for the
alkaloid extraction from Chelidonium majus [11].
Method A. Five grams of the dry plant material (Eschscholzia
californica, Arcopharma, AMM 57426001, Switzerland) in a
form of green powder was extracted into 100mL of methanol
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Figure 2: (a) LC UV chromatogram of Eschscholzia californica extract before fractionation. Peak identification: (1) reticuline; (2) caryachine;
(3) N-methyllaurotetanine; (4) protopine; (5) californidine; (6) allocryptopine; (7) escholtzine; (8) sanguinarine; and (9) chelerythrine. (b)
LC-MS trace of “NMT sample” containing 82% N-methyllaurotetanine, 10% reticuline, and 8% caryachine with traces of other alkaloids.
(15 minutes at 60∘C). Organic solvent (95mL) was then
distilled out at the rotary evaporator at the reduced pressure.
Green-coloured solution was diluted with 50mL of distilled
water and solution pHwas adjusted to 1.0 (drop-wise addition
of 10% hydrochloric acid). Subsequently, 100mg of 0.2 wt%
sodium dodecyl sulfate (aq.) was added and alkaloids were
extracted with chloroform (3 × 50mL). The organic phase
was dried using anhydrous Na
2
SO
4
and the chloroform
evaporated using the rotary evaporator at 40∘C. Finally, the
crude extract was dissolved in 10mL MeOH and filtered
using 5.0 𝜇m followed by 0.45 𝜇mPTFEmicrofilter.The plant
extract was then subjected to a thin-layer chromatography
(TLC) in methylene chloride/methanol (18 : 2) containing
0.1% trifluoroacetic acid as mobile phase. TLC spots were cut
out using the razor blade, extracted into 5mL methanol, and
subjected to ESI-MS/MS analysis. Electrospray ionization
high-resolution mass spectra were acquired with a FT/ICR
mass spectrometer Bruker 4.7T BioApex II (Germany).
Alkaloids were also separated and identified using the diode-
array HPLC and commercial alkaloid standards. Figure 1
illustrates a typical alkaloid distribution in E. californica
found in the present study using the HPLC and ESI-
MS/MS (see Supplementary material available online at
http://dx.doi.org/10.1155/2015/617620).
Method B. E. californica was obtained from Dixa AG (St
Gallen, Switzerland) and a voucher sample was deposited at
Interdelta (Givisiez, Switzerland) under the number 132914.
The finely ground dry aerial part of E. californica (1.872 kg)
was macerated in methanol for 10 weeks. Methanol was
evaporated. The weight of dry extract was 412.5 g (22% of
dry material). HPLC chromatogram of the extract before
fractionation is shown in Figure 2(a). The dry plant extract
was dissolved in 1% aq.H
2
SO
4
, aqueous phasewas adjusted to
pH ≅ 9 and alkaloid fraction was extracted into diethylether.
Fraction A (8.06 g) was obtained once diethylether was
distilled off. In order to isolate NMT, the plant sample was
fractionated into two fractions: A1 (nonphenolic alkaloids)
and A2 (phenolic alkaloids). Fraction A was dissolved in 1%
H
2
SO
4
, pH was adjusted to 13, and nonphenolic alkaloids
were extracted into diethylether (fraction A1).The remaining
aqueous phase was acidified to pH 8 with H
2
SO
4
and
extracted second time into diethylether (fraction A2, pheno-
lic). After evaporation of diethylether the mass of fraction A1
contained 4.19 g and the mass of the fraction A2 contained
2.02 g. Fraction A2 was found to contain 82% NMT, 10%
reticuline, and 8% caryachine (Figure 2(b)). The method was
described in our previous study [12]. Briefly, themobile phase
was prepared from a stock solution of 0.01M sodium 1-
heptanesulfonate and 0.1M triethylamine in H
2
O, adjusted
to pH 2.5 with phosphoric acid. Mobile phase A consisted of
25 : 75 (v/v) acetonitrile (ACN) : stock solution.Mobile phase
B was 60 : 40 (v/v) ACN : stock solution. Phosphoric acid
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and sodium 1-heptanesulfonate were obtained from Sigma-
Aldrich (Prague, Czech Republic). ACN (HPLC grade) was
purchased fromMerck (Darmstadt, Germany).The following
elution profile was employed: 0–4min isocratically 100%
A; 4–15min 0–20% B; 15–38min 45% B; 38–50min 80%
B; and 50–60min isocratically 100% A. The flow rate was
set to 0.5mL/min, the injection volume was 100𝜇L, and
detection was performed using DAD (diode-array detector)
at 280 nm. The identification of separated alkaloids was
based on comparison of their retention times with those
of authentic standards. Quantitative analysis was performed
using external standards. The HPLC apparatus consisted of
a LC-20 AD high-pressure gradient pump LC-20 AD, SPD
M20A diode-array detector (Shimadzu, Japan) and a syringe-
loading sample injector (ECOM, Czech Republic) with a
20-𝜇L external sample loop. Alkaloids were separated on
a C12 column (Synergi RP-Max, 4𝜇m, 150 × 4.60mm ID,
Phenomenex, CA).
The LC-MS method used to identify the “NMT fraction”
alkaloids (Figure 2(b)) was developed using Dionex Ultimate
3000RS (Thermo Scientific, CA) module. Compound sepa-
ration was achieved with 3.0 × 150mm, 5 𝜇m Synergi RP-
Max C18 (Phenomenex) column at 23∘C and a flow rate of
0.5mL/min. The binary mobile phase system consisted of
0.1% formic acid and LC-MS grade ACN (both Sigma). After
20-𝜇L injection, ACN was linearly increased from 20% to
40% over 10min and then to 80% over the next 10min. ACN
was held at 80% for 10min, followed by equilibration at the
initial conditions for 3.0min. A complete HPLC run was
33min. The HPLC system was connected to a MicrOTOF-
QII (Bruker, Germany) mass spectrometer, operated in pos-
itive electrospray ionisation mode. The ionisation conditions
were set by the software as follows: the capillary voltage
4.5 kV, end plate offset −0.5 kV, source temperature 220∘C,
desolvation gas (nitrogen) flow 10 L/min, nebuliser (nitrogen)
pressure 3 bar, and collision cell voltage 35 eV. The base-
peak chromatogram (BPC) was acquired in MS mode by
monitoring the range of 50 to 3000m/z with a spectra sample
time of 1 s. The identification of target compounds relied on
isotope pattern matching with a combination of MS/MS and
retention behaviour. High-resolutionMS andMS/MS spectra
were first investigated to obtain the elemental formula of each
compound. A compound was unambiguously identified if
the fragmentation patterns of the unknown and the target
alkaloid were identical.
2.3. Electrophysiological Experiments. Capped cRNAs were
synthesized from the linearized plasmids. A poly-A tail of
about 400 residues was added to each transcript using yeast
poly-A polymerase. The concentration of the cRNA was
quantified on a formaldehyde gel using Radiant red stain for
visualization of the RNA. Known concentrations of RNA lad-
der were loaded as standard on the same gel. cRNAswere pre-
cipitated in ethanol/isoamylalcohol 19 : 1 and the dried pellet
was dissolved in water and stored at −80∘C. Xenopus oocytes
(Centre de Ressources Biologiques Xe´nopes, UMS 3387,
Universite´ de Rennes, France. Animal research permit by the
Kantonstierarzt, Kantonaler Veterina¨rdienst Bern (BE98/12))
were prepared, injected, and defolliculated as described
previously [13]. Briefly, Xenopus laevis oocytes were injected
with 50 nL of the cRNA solution containing 𝛼
1
, 𝛼
2
, 𝛼
3
, 𝛼
5
,
or 𝛼
6
in combination with 𝛽
1
, 𝛽
2
, or 𝛽
3
and 𝛾
2
subunits at
a concentration of 10 nM : 10 nM : 50 nM and then incubated
in modified Barth’s solution at 18∘C for at least 24 h before
themeasurements. For𝛼
1
𝛽
2
𝛿 10 nM : 10 nM : 50 nMwas used.
Currents were measured using a home-built two-electrode
voltage clamp amplifier in combination with XY-recorder or
digitized using a PowerLab 2/20 (AD Instruments) using the
computer program Chart. Tests with a model oocyte were
performed to ensure linearity in the larger current range.
The response was linear up to 15 𝜇A. Electrophysiological
experiments were performed by using the two-electrode
voltage clamp method at a holding potential of −80mV. The
perfusion medium contained 90mMNaCl, 1mM KCl, 1mM
MgCl
2
, 1 mM CaCl
2
, and 5mMNa-HEPES (pH 7.4) and was
applied by a gravity flow of 6mL/min. Allosteric modulation
was measured at a GABA concentration eliciting 0.5–1.5% of
the maximal GABA current amplitude in the corresponding
receptor. GABA was applied for 20 s alone or in combination
with allosteric compound.The perfusion system was cleaned
between drug applications by washing with DMSO to avoid
contamination. Drugs were dissolved at 10mM in DMSO
and stored at −20∘C. The final concentration of DMSO in
the experiment was <0.5%. This concentration of DMSO did
not affect currents elicited by GABA.The silicon-coated glass
tubes were used for dilutions. These diluted solutions were
always prepared fresh immediately before the experiment.
3. Results
3.1. Alkaloid Identification andQuantification. Figure 1 shows
the chemical structure for all fourteen E. californica alkaloids
identified in the present work. Nine of these were quantified
using HPLC and appropriate alkaloid standards (Table 1),
while the remaining compounds were positively identified
by LC-MS and ESI-MS/MS (see Figures 2 and 3 and Figures
S1–S8) and compared to previously reported MS data [9].
The advantage of this approach stems from the fact that each
of studied alkaloids gives only one parent ion (+1) which
can be further fragmented by tandem MS/MS so that each
alkaloid had its own MS fingerprint signature and can be
easily identified even though it is present in complex alkaloid
mixtures (see Supplementary Material). It was suspected [12]
that protopine and allocryptopine levels in the aerial parts
of E. californica could be higher compared to relatively rapid
alkaloid extraction (Method A) providing dry herb material
would be macerated in methanol solutions for extended
periods of time (Method B). It is evident from the data shown
in Table 1 that even after 10 weeks of maceration the amount
of protopine is rather low and about 43-fold higher than that
of allocryptopine.On the other hand, and in contrast to rather
low protopine yields, the NMT exceeds 11-fold amounts of
protopine and its level is comparable to that of eschscholtzine.
Unfortunately, the former compound was misinterpreted
when analysing ESI-MS/MS data by Fabre et al. [14]. It is
evident from theMS/MS fragmentation pattern shown in our
Figure 3(b) thatm/z 354.1 corresponds to this pavine alkaloid
6S,12S-neocaryachine-7-O-methyl ether N-metho salt rather
Biochemistry Research International 5
Table 1: Alkaloid content determined using LC-diode array spectrophotometry in the aerial part of E. californica. The amount of alkaloid
is expressed as mg/g of dry weight (mean ± standard deviation (𝑛 = 2)). Five grams of finely ground plant material was macerated (a) in
methanol for 5 days and after SDS-based extraction in chloroform (Soxhlet apparatus) and (b) 10-week extraction in methanol solution from
1.872 kg of dried plant material.
(a)
Alkaloid (mg/g)
NMT PRO CAL ALL ESCH SA CHE
CH
3
OH 0.702 ± 0.159 0.137 ± 0.057 2.413 ± 0.331 0.035 ± 0.016 0.902 ± 0.074 0.041 ± 0.002 0.019 ± 0.003
CHCl
3
-SDS 0.557 ± 0.138 0.136 ± 0.113 1.951 ± 0.415 0.037 ± 0.010 0.545 ± 0.086 0.040 ± 0.015 0.022 ± 0.100
(b)
Alkaloid (mg/g)
Protopine (PRO) 0.514 ± 0.038
Californidine (CAL) 12.5 ± 1.8
Allocryptopine (ALL) 0.0120 ± 0.0023
Eschscholtzine (ESCH) 8.700 ± 0.51
Sanguinarine (SA) 0.0191 ± 0.0050
Chelerythrine (CHE) 0.068 ± 0.011
Reticuline (RE) 1.095 ± 0.16
N-Methyllaurotetanine (NMT) 5.68 ± 0.72
Caryachine (CAR) 0.410 ± 0.065
O
O N
O
O
O
[Protopine+H]+
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In
te
ns
.
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te
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te
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Figure 3: (a) (A) Electrospray ESI trace and (B) tandem MS/MS fragmentation pattern for selected ion m/z 354 corresponding to alkaloid
protopine detected in a pharmacy capsule (300mg) of E. californica (AMM 57426001) following alkaloid extraction and separation (Method
A). (b) Electrospray ESI trace (A) and tandem MS/MS profile (B) for 6S,12S-neocaryachine-7-O-methyl ether N-metho salt detected in the
same AMM 57426001 sample. Note that m/z 354 for this pavine alkaloid is practically identical to that of protopine; however, it gives quite
different fragmentation pattern.
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than protopine—as claimed in Figure 5 by Fabre and cowork-
ers [14]. Note that the molecular mass of both compounds
is practically identical. This is rather unfortunate since their
work, considered as reference in the area of alkaloid detection
in Papaveraceae plants, actually missed to detect protopine—
suggested as one of active principles in thismedicinal herb. In
addition to NMT, we have identified relatively high amount
of reticuline (>1mg/g of dry matter) in the aerial parts of
E. californica (Table 1). This is quite important observation
considering possible biological activity of this alkaloid (see
below). Detection of reticuline in this plant was probably
missed in older studies due to the lack of its separation from
NMT at the HPLC columns used.
3.2. Biological Effects of E. californica Alkaloids. Protopine
and allocryptopine are expected to act on GABAA receptors
in the micromolar range [5]. It is clear that levels of both
alkaloids in E. californica analysed in the present study
(Table 1) are relatively low and, therefore, submicromolar
protopine levels in a single pharmacy capsule (300mg)
should fail to modulate the opening of the GABAA receptors
in vitro and in vivo. Since our E. californica extracts were
found to contain relatively large amounts of NMT, it was
suspected that this molecule could bind to GABAA receptors
and be responsible for sedation. Interestingly, the preliminary
radiotelemetry experiments in C5BL/6J mice fed with the
NMT-enriched fraction (82% NMT, 10% reticuline, and 8%
caryachine with other minor alkaloids (Figure 2(a)) showed
short-term sedative effects in a dose of 10mg/kg between 30
and 54min after oral administration (unpublished work by
V. Butterweck, J. Wedler, University of Florida, Gainesville).
In order to understand whether such sedation is due to NMT
binding to GABAA receptors, the electrophysiological studies
were conducted using highly purified NMT (99.8%).
E. californica alkaloid binding on GABAA receptors (in
vitro) was not studied so far because of the presence of 𝛾-
aminobutyric acid in the plant extracts [9]. Therefore, we
have studied effects of pure NMT on recombinant GABAA
receptors using electrophysiological technique. Typically,
four milligrams of highly purified NMT was dissolved in
a stock DMSO solution and appropriate dilutions were
made for titrations at recombinant 𝛼
1
𝛽
2
𝛾
2
GABAA receptors.
Interestingly, NMT titrations have revealed no allosteric
modulation up to 30 𝜇M. Stimulation by 1 𝜇M diazepam
was not decreased by 10 𝜇M NMT, excluding an antago-
nistic effect at the benzodiazepine binding site. Similarly,
protopine had no significant effects up to a concentration
of 30 𝜇M. Additional experiments were performed with
(S)-reticuline HCl salt (>90% isomer provided by Toronto
Research Chemicals). Again, no significant effects of this
molecule on recombinant 𝛼
1
𝛽
2
𝛾
2
receptors were noticed for
concentrations below 10𝜇M. Instead, about 28% inhibition
of chloride currents was observed in the presence of 30𝜇M
(S)-reticuline (Figure 4). A similar behaviour was observed
upon exchanging 𝛽
2
subunit by 𝛽
1
or 𝛽
3
and in 𝛼
1
𝛽
2
𝛿
receptors (Figure 4). Excitingly, (S)-reticuline performed as
a positive allosteric modulator at 𝛼
3
𝛽
2
𝛾
2
, 𝛼
5
𝛽
2
𝛾
2
, and 𝛼
6
𝛽
2
𝛾
2
receptors. Maximal stimulation was in each case about 100%
of the maximal GABA effect and half-maximal stimulation
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Figure 4:Modulation of recombinant GABAA receptors of different
subunit composition by (S)-reticuline. Receptors were expressed
in Xenopus oocytes and concentration dependent modulation was
determined using electrophysiological techniques. Each curve is the
average of three to four determinations (data points ± standard
deviation).
(EC
50
) was observed at about 6 𝜇M. In contrast at 𝛼
2
𝛽
2
𝛾
2
receptors we observed allosteric inhibition (Figure 4). 10 𝜇M
(S)-reticuline did not by itself elicit currents in 𝛼
3
𝛽
2
𝛾
2
receptors. As in the case of 𝛼
1
𝛽
2
𝛾
2
receptor, only a small
inhibition was observed at high concentration at 𝛼
1
𝛽
1
𝛾
2
,
𝛼
1
𝛽
3
𝛾
2
, and 𝛼
1
𝛽
2
𝛿 receptors. While (R)-reticuline had no
effect (see below), the modulatory effect by (S)-reticuline
was stereospecific. As Figure 5 documents, 1 𝜇M Ro15-1788,
an antagonist acting at the benzodiazepine binding site, did
not inhibit the potentiation by 10 𝜇M (S)-reticuline in 𝛼
3
𝛽
2
𝛾
2
receptors but rather stimulated its action. This indicates that
(S)-reticuline does not act at the benzodiazepine binding site.
It may be speculated that (S)-reticuline contacts at least one
amino acid residue of the 𝛼 subunit that is similar in 𝛼
3
, 𝛼
5
,
and 𝛼
6
but different from the homologous residue in 𝛼
2
and
both must be different from the homologous residue in 𝛼
1
.
Alignment of the sequences of all 𝛼 subunits reveals that only
few positions qualify as part of the binding site.
Suspected (S)-reticuline metabolites in the rodent organ-
ism were also tested for modulation. Interestingly, recombi-
nant 𝛼
1
𝛽
2
𝛾
2
, 𝛼
3
𝛽
2
𝛾
2
, and 𝛼
5
𝛽
2
𝛾
2
GABAA receptors were not
significantly affected by 10𝜇M of either (R)-reticuline, 1,2-
tetrahydroreticuline, codeine, or morphine (not shown).
4. Discussion
During the last three decades, several analytical studies have
addressed the issues of alkaloid detection and quantification
in green parts of E. californica [14–16]. Unfortunately, signifi-
cant differences in the alkaloid content have been noticed. For
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Figure 5: Effect of a benzodiazepine antagonist on the potentiation of𝛼
5
𝛽
2
𝛾
2
GABAA receptors by (S)-reticuline. Application of 0.5 𝜇MGABA
was followed by application of 0.5𝜇MGABA/10 𝜇M (S)-reticuline and subsequently by 0.5𝜇MGABA/10 𝜇M (S)-reticuline/1 𝜇MRo15-1788.
Providing (S)-reticuline would act at the benzodiazepine site elicited currents would be expected to go back to the size elicited by GABA
alone. Instead, a potentiation was observed. Similar observations were made in two additional experiments.
example, protopine levels were found to vary by two orders
of magnitude going from traces [9, 14, 16] to comparable
levels to those of californidine and eschscholtzine [15]—two
most abundant alkaloids in this plant. In order to make
sure that the majority of alkaloids get extracted from the
dried plant tissues, we have conducted their maceration in
methanol up to 10 weeks, which was followed by alkaloid
quantification by diode-array HPLC. We were especially
interested in protopine and allocryptopine levels since both
alkaloids were suggested to act at the GABAA receptor [5, 6].
The electrophysiological experiments conducted in the
present work at various GABAA receptor isoforms suggest
that protopine does not play significant role regarding the
sedative effects of E. californica reported in previous studies.
Typical recommendation for the E. californica dose is two
300mg capsules of dry plant material before sleep (https://
www.swissmedic.ch/zulassungen/00153/00189/00200/01041/
index.html?lang=de). It is evident from HPLC analysis
(Table 1) that protopine and 𝛼-allocryptopine levels in the
aerial parts of this herb are too low to modulate significantly
the chloride-ion flow across the GABAA receptors. Both
protopine and allocryptopine are known as inhibitors of
the human serotonin and noradrenaline transporters [10];
however, 0.01–0.5mg/g of these alkaloids is certainly too low
to boost the serotonin or noradrenaline levels in depressed
patients. Hanus and colleagues [4] have conducted double-
blind placebo-controlled study to evaluate the efficacy
and safety of E. californica in combination with Crataegus
oxyacantha extracts for the treatment of mild-to-moderate
anxiety disorders. However, Crataegus is known to contain
several flavonoids such as quercetin and rutin, flavonol
kaempferol, and other compounds known to act on the
central nervous system [17]. Quercetin and kaempferol
have been reported to bind at the GABAA receptors [18],
which was suggested to explain sedative and anxiolytic
effects of these compounds [18–20]. Quercetin also agonizes
5HT1A receptor in vitro and it has been suggested as a
candidate to explain its antinociceptive properties [21]. Even
though several flavone glycosides of quercetin, rutin, and
isorhamnetin were previously detected in E. californica [22],
we could detect only traces of kaempferol in aerial parts of
this plant (HPLC data not shown). However, NMT appears
as a relatively strong antagonist with respect to the 5HT1A
receptor [9] and, as the result, it is unlikely to promote
antinociceptive effects of E. californica. Therefore, there must
exist another mechanism of how this plant affects the central
nervous system in mammals. Interestingly, we have shown
in the present work that aerial parts of E. californica contain
(S)-reticuline. It has been shown [23] that this compound
may be transformed by neuroblastoma cells into morphine,
which is known to bind to 𝜇-opioid receptors. The latter
observation could explain why pure (S)-reticuline isolated
from Ocotea duckei acted as potent central nervous system
depressant [24].
Telemetry experimentswith 10% (S)-reticuline, present in
the NMT fraction, showed sedative effects onmice. However,
our electrophysiological experiments have clearly established
that there is no positive modulation of chloride currents by
(S)-reticuline at the recombinant 𝛼
1
𝛽
2
𝛾
2
GABAA receptors,
the main isoform in the brain thought to mediate sedative
effects. Therefore, (S)-reticuline is likely to get metabolized
in rodents to some other compoundmanifesting significantly
higher modulation of GABAA receptors than the parent
molecule. It has been reported [25] that (S)-reticuline may
be metabolized in rodents via 1,2-dehydroreticuline, (R)-
reticuline, and other alkaloid intermediates into codeine
and morphine. In this respect, Nikolaev and colleagues [26]
monitored G
𝑖
-protein activation in living HEK293a cells
expressing human 𝜇-opioid receptors (MOR) and tested
binding of morphine and codeine. The binding constant at
MOR was determined in the nanomolar range (𝐾
𝑖
= 4 ±
1 nM), with EC
50
= 6 ± 2 nM for G
𝑖
activation by mor-
phine. Codeine appeared to havemuch lower antinociceptive
potency with both the 𝐾
𝑖
-constant and EC
50
of 6 𝜇M. Both
of these molecules are also formed in Papaveraceae family
plants via successive biochemical transformations of (S)-
reticuline—the morphine being the final alkaloid product
[25].
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Immunoreactivity staining of the adult mouse brain colo-
calized endogenous morphine and codeine with GABAergic
interneurons and astrocytes [27]. Morphine concentrated in
a small population of neurones could function as a neu-
romodulator able to affect indirectly the inhibitory activity
of GABAergic neurons. In particular, parvalbumin- (PV-)
positive terminals of basket cells (GABAergic interneurons)
express 𝜇-opioid receptors andM2muscarinic receptors, tar-
geting the somatic part of pyramidal neurons equipped with
𝛼
1
subunit-containing GABAA receptors [28, 29]. This is in
contrast to cholecystokinin- (CCK-) positive interneurons—
expressing mainly cannabinoid CB1 and estrogen and
metabotropic GABAB receptors. Since alkaloids coming from
(S)-reticuline biotransformation are able to bind to 𝜇-opioid
receptors, this could in turn affect GABA release at the
PV terminals of the inhibitory cells and be responsible for
mild sedative effects observed in our telemetric experiments.
Providing there is even distribution and little degradation
of (S)-reticuline, the level of 3 𝜇M in the rodent brain may
be estimated. This is also high enough to affect 𝛼
3
𝛽
2
𝛾
2
and
𝛼
5
𝛽
2
𝛾
2
GABAA receptors.The rat brain level of (S)-reticuline
has been estimated as 13 ng/g [30], corresponding to an
average concentration of about 0.05 𝜇M. On the other hand,
only a small fraction of the neurons contains morphine
metabolites—that is, mainly GABAergic neurons [31].There-
fore such a reticuline metabolite-dependent modulation of
inhibitory interneurons may be relevant to in vivo situation.
5. Conclusion
ESI-tandem MS/MS and HPLC allowed us to detect, iden-
tify, and quantify majority of alkaloids present in E. cali-
fornica. Modulation of chloride currents by protopine, 𝛼-
allocryptopine, NMT, and reticuline at different recombinant
GABAA receptor isoforms was studied in vitro. Our choice of
studying NMT and reticuline comes from the fact that the
“NMT fraction” (see Section 3.2) manifested mild sedative
effects on mice. On the other hand, much more abundant
californidine (a quaternary pavine alkaloid) is unable to
penetrate the brain-blood barrier [32] and, therefore, was not
included in our electrophysiological study. The main goal of
the present work was to identify the mechanism by which E.
californica alkaloids could induce sedative effects. The main
finding of the present work is that sedation caused by this
medicinal herb does not depend on direct binding of alka-
loids to GABAA receptors and chloride current modulation.
Even though (S)-reticuline was found to act on 𝛼
3
𝛽
2
𝛾
2
and
𝛼
5
𝛽
2
𝛾
2
GABAA receptors, eventually, it may get transformed
in the mammal body into more potent alkaloids which are
then able to bind to GPCR receptors in the nanomolar range.
We believe that mild sedative and antinociceptive properties
of dry aerial parts of E. californicamay be assigned to binding
of morphine (and/or other alkaloids) at the 𝜇-opioid recep-
tors. Morphine may be generated in the rodent organism
via successive biotransformation of (S)-reticuline present in
aerial parts of E. californica. The presence of this alkaloid
in aerial parts of California poppy was probably missed in
previous studies since tis molecule probably coeluted with
NMT under typical HPLC conditions [14].
In conclusion, in order to achieve important medicinal
effects (regarding relatively low alkaloid levels determined in
aerial parts of this plant), one would need either to increase
the dried plant dosage above 1 g before sleep, or, eventually, to
combine E. californicawith other medicinal herbs containing
other sleep-promoting alkaloids.
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